Cipla | CIPLA - Operating Profit


Cipla reported INR6.14B in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cipla INR 6.14B 3.63B Mar/2026
Dr.Reddys Laboratories INR 888M 13.05B Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sun Pharmaceuticals INR 40.62B 6.95B Dec/2025
TherapeuticsMD USD -1.18M 40K Jun/2024
UPL INR 27.32B 11.26B Mar/2026